NewLink Genetics is to conduct an investigator-initiated, randomized, double-blind, placebo-controlled, Phase II trial of sipuleucel-T + indoximod (D-1MT/NLG8189) in the treatment of men with asymptomatic or minimally symptomatic, metastatic, castration-resistant prostate cancer (mCRPC).
According to the media release on the Yahoo!Finance web site, this study with be conducted in collaboration with Dendreon Corporation and the Masonic Cancer Center at the University of Minnesota.
Indoximod is a so-called IDO pathway inhibitor and affects expression of the IDO enzyme that regulates immune response by suppressing T-cell function and enabling local tumor immune escape. Some more information about this product is available on the NewLink Genetics web site. The details about this trial are not yet posted to the ClinicalTrials.gov web site. For more information you will currently need to contact NewLink Genetics by phone (515-296-5555) or by e-mail.
Like this:
Be the first to like this.
Filed under: Management, Drugs in development Tagged: | castration-resistant, sipuleucel-T, metastatic, mCRPC, indoximod
Source: http://prostatecancerinfolink.net/2012/09/21/phase-ii-trial-of-sipuleucel-t-indoximod-in-mcrpc/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.